The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell

Molecular and Cellular Biochemistry

Volumn 386, Issue 1-2, 2014, Pages 117-124

  Liu, Kun ^a   Chen, Honglin ^a   You, Qingsheng ^a   Shi, Hai ^a   Wang, Zhiwei ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Gastric cancer; HER2; SGC 7901; siRNA; siRNA cocktail; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, ERBB-2; HUMANS; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84891559878     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1850-0     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108
2. Jemal A, Bray F, Center MM, et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
3. Tai W, Mahato R, Cheng K (2010) The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 146(3):264-275
4. Jørgensen JT (2010) Targeted HER2 treatment in advanced gastric cancer. Oncology 78(1):26-33
5. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9):1523-1529
6. Carmeliet P (2005) VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology 69(3):4-10
7. Chen J, Li T, Wu Y, et al. (2011) Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol 137(12):1799-1812
8. Ohtsu A, Shah MA, Van Cutsem E, et al. (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968-3976
9. Vert JP, Foveau N, Lajaunie C, et al. (2006) An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 7:520
10. Rhim JS, Tsai WP, Chen ZQ, et al. (1998) A human vascular endothelial cell model to study angiogenesis and tumorigenesis. Carcinogenesis 19(4):673-681
11. Tan M, Yu D (2007) Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol 608:119-129
12. Nathanson DR, Culliford AT 4th, Shia J, et al. (2003) HER2/neu expression and gene amplification in colon cancer. Int J Cancer 105(6):796-802
13. Tetu B, Fradet Y, Allard P, et al. (1996) Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 155(5):1784-1788
14. Tuefferd M, Couturier J, Penault-Llorca F, et al. (2007) HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2(11):e1138
15. Berchuck A, Rodriguez G, Kinney RB, et al. (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164(1 Pt 1):15-21
16. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. (2005) Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23(22):5007-5018
17. Rosty C, Couturier J, Vincent-Salomon A, et al. (2004) Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol 23(1):13-17
18. Rait AS, Pirollo KF, Ulick D, et al. (2003) HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann N Y Acad Sci 1002:78-89
19. Mimura K, Kono K, Maruyama T, et al. (2011) Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer 129(10):2408-2416
20. Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97(4):453-457
21. Kaufmann R, Müller P, Hildenbrand G, et al. (2011) Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. J Microsc 242(1):46-54
22. Park DI, Yun JW, Park JH, et al. (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51(8):1371-1379
23. Zhao W, Yue L, Zhou F, et al. (2013) Clinical significance of vimentin expression and her-2 status in patients with gastric carcinoma. Clin Transl Sci 6(3):184-190
24. Choudhury A, Charo J, Parapuram SK, et al. (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108(1):71-77
25. Kim ES, Serur A, Huang J, et al. (2002) Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99(17):11399-11404
26. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417-427
27. Zhu AX, Sahani DV, Duda DG, et al. (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27(18):3027-3035
28. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
29. Hayes DF (2011) Bevacizumab treatment for solid tumors: boon or bust? JAMA 305(5):506-508
30. Haussecker D (2012) The Business of RNAi Therapeutics in 2012. Mol Ther Nucleic Acids 1:e8
31. Barros SA, Gollob JA (2012) Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 64(15):1730-1737
32. Li JM, Wang YY, Zhang W, et al. (2013) Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA. Int J Nanomedicine 8:2101-2117
33. Kenjo E, Asai T, Yonenaga N, et al. (2013) Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy. Biol Pharm Bull 36(2):287-291
34. Eccles SA (2001) The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6(1):393-406